Sei Investments Co. Has $7.15 Million Stake in iRadimed Corporation $IRMD

Sei Investments Co. increased its position in shares of iRadimed Corporation (NASDAQ:IRMD) by 17.2% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 74,304 shares of the medical equipment provider’s stock after acquiring an additional 10,908 shares during the period. Sei Investments Co.’s holdings in iRadimed were worth $7,153,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of IRMD. Tudor Investment Corp ET AL bought a new stake in shares of iRadimed during the third quarter worth about $666,000. Baader Bank Aktiengesellschaft bought a new position in iRadimed in the 4th quarter valued at approximately $595,000. Bridge City Capital LLC boosted its position in iRadimed by 19.4% during the 4th quarter. Bridge City Capital LLC now owns 70,854 shares of the medical equipment provider’s stock worth $6,893,000 after buying an additional 11,509 shares during the period. RFG Advisory LLC acquired a new stake in iRadimed during the 4th quarter worth approximately $1,594,000. Finally, Victory Capital Management Inc. boosted its position in iRadimed by 23.3% during the 3rd quarter. Victory Capital Management Inc. now owns 26,565 shares of the medical equipment provider’s stock worth $1,890,000 after buying an additional 5,021 shares during the period. Institutional investors and hedge funds own 92.34% of the company’s stock.

Insider Buying and Selling

In other iRadimed news, CEO Roger E. Susi sold 2,500 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total transaction of $226,500.00. Following the completion of the sale, the chief executive officer owned 2,162,500 shares of the company’s stock, valued at approximately $195,922,500. This represents a 0.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 17,500 shares of company stock valued at $1,515,065 in the last quarter. Corporate insiders own 34.60% of the company’s stock.

iRadimed Stock Performance

Shares of IRMD opened at $90.86 on Monday. The company has a market capitalization of $1.16 billion, a PE ratio of 50.76 and a beta of 0.90. iRadimed Corporation has a 12 month low of $57.83 and a 12 month high of $107.90. The stock’s 50-day moving average price is $94.54 and its two-hundred day moving average price is $95.68.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. The firm had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed had a return on equity of 23.73% and a net margin of 26.70%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Equities research analysts predict that iRadimed Corporation will post 1.52 EPS for the current fiscal year.

iRadimed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 28th. Investors of record on Friday, August 14th will be issued a $0.20 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s dividend payout ratio is presently 44.69%.

iRadimed News Summary

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
• Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
• Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.